1. The association between interleukin-8 levels and the development of withdrawal symptoms during methamphetamine abstinence.
- Author
-
Feng L, He W, Lin S, Ruan Y, Yuan C, Qiu H, Ren W, and He J
- Subjects
- Adult, Amphetamine-Related Disorders blood, Female, Follow-Up Studies, Humans, Male, Methamphetamine administration & dosage, Prospective Studies, Substance Withdrawal Syndrome blood, Surveys and Questionnaires, Young Adult, Amphetamine-Related Disorders rehabilitation, Interleukin-8 blood, Methamphetamine adverse effects, Substance Withdrawal Syndrome physiopathology
- Abstract
Objective: Withdrawal symptoms are common during methamphetamine (METH) abstinence. This study aimed to explore the association between serum interleukins and withdrawal symptoms during METH abstinence., Methods: This study recruited 120 METH users, and 94 of them completed the 2-week follow-up. Serum interleukin-1β, 6,8,10 were tested at admission. Withdrawal symptoms were assessed by the Methamphetamine Withdrawal Questionnaire (MAWQ)., Results: Serum IL-8 levels were positively correlated with MAWQ scores at the 2-week endpoint (r = .257, p = .013). The variation of the MAWQ scores during the 2-week follow-up was negatively correlated with serum IL-8 levels at admission (r = -.249, p = .026). Serum IL-8 levels remained associated with the severity of METH withdrawal symptoms (β = .363, p = .023), after adjusting for potential confounders., Limitations: This study did not include normal controls. Most patients were male and cigarette smokers. Patients were only followed up for 2 weeks, and their toxicology data were not collected. Interleukins were only measured at admission, and were tested in serum, not in the cerebrospinal fluid., Conclusions: Our study demonstrated that higher serum IL-8 levels may predict more severe withdrawal symptoms at 2 weeks after METH abstinence., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF